Comparing the current results to its competitors, Biodexa Pharmaceuticals Plc reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, slower than the combined decrease of the BDRX's competitors by -9.84 %, recorded in the same quarter.
Biodexa Pharmaceuticals Plc's Comment on Competition and Industry Peers
The company faces competition from commercial pharmaceutical and biotechnology firms, academic institutions, government agencies, and private and public research organizations. Competitors often possess greater research capabilities and more extensive financial, product development, manufacturing, and marketing resources. Currently, there are no approved products for the familial adenomatous polyposis (FAP) indication, although some non-steroidal anti-inflammatory drugs may be prescribed off-label. Tempest Therapeutics, Inc., Panbela Therapeutics, Inc., and Recursion Pharmaceuticals, Inc. are developing products targeting FAP. For non-muscle invasive bladder cancer (NMIBC), the standard treatment includes transurethral resection followed by intravesical Bacillus Calmette-Guérin therapy. Several companies, including Janssen, are developing therapeutics for NMIBC.
February 23, 2024
Biodexa Pharmaceuticals PLC Presents Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides RandD UpdateIn a recent press release, Biodexa Pharmaceuticals PLC (Biodexa) announced the positive top line results of its phase I clinical trial for the treatment of Diffuse Midline Glioma (DMG). This groundbreaking research offers hope for patients suffering from this aggressive and deadly tumor, providing new possibilities in their fight against the disease. Additionally, Biodexa shared an update on its research and development (RandD) activities, highlighting its commitment to advancing the field of pharmaceutical sciences.Clinical Trial ResultsThe phase I clinical trial conduct...
In a groundbreaking development within the pharmaceutical industry, Biodexa Pharmaceuticals PLC (Biodexa) has successfully completed the recruitment for Cohort A in its study of MTX110, a potential treatment for recurrent glioblastoma. Simultaneously, the company has exceeded expectations by achieving a remarkable revenue increase in the fourth quarter of 2022. This article aims to shed light on these developments, comparing Biodexa s achievements with that of its competitors, and exploring the potential impact of their innovative research on the treatment of such a devastating disease. Biodexa s Ambitious Research Study: Glioblastoma, an aggressive type of brain cancer, has long confounded...
Publicly Traded Peers of Biodexa Pharmaceuticals Plc
Ardelyx inc Share Performance
-2.56%
Over The Past 5 Days
Ardelyx inc
Profile
Ardelyx Inc is a biopharmaceutical company that focuses on the development of novel, minimally-absorbed small molecules to treat gastrointestinal diseases. Their business model revolves around identifying specific needs within the gastrointestinal field and leveraging their research and development capabilities to create innovative therapeutic solutions. By partnering with other pharmaceutical companies and pursuing strategic collaborations, Ardelyx aims to bring its products to market and ultimately improve patient outcomes in the gastrointestinal space.
Intra Cellular Therapies Inc operates as a biopharmaceutical company that focuses on the discovery and development of innovative therapeutics for the treatment of neuropsychiatric and neurodegenerative diseases. Their business model involves conducting research and clinical trials to validate the efficacy and safety of their drug candidates. Once successful, they aim to gain regulatory approvals, form strategic partnerships, and commercialize their products to provide medical solutions for patients suffering from these challenging conditions.
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in the development and aseptic manufacturing of sterile injectable pharmaceuticals.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Biodexa Pharmaceuticals Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biodexa Pharmaceuticals Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
